Skip to main content
. 2019 Sep 17;10(53):5510–5522. doi: 10.18632/oncotarget.27140

Figure 6. The progression free survival (PFS) analysis of metastatic colorectal cancer patients who underwent evaluation of ERCC1 kinetics (n=24).

Figure 6

13/24 had an increase in ERCC1 expression, with a corresponding median PFS of 190 days. This was significantly lower than the PFS of patients who had no change or decrease in ERCC1 expression kinetics (237 days, p= 0.018).